Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Crit Care Med. 2012 Jun;40(6):1857–1863. doi: 10.1097/CCM.0b013e318246bb5d

Figure 4.

Figure 4

Calpain and Caspase-3 activity in the diaphragm of all four experimental groups. A) The active form of calpain 1 in diaphragm muscle at the completion of 12 hours of MV. B) Levels of the 145 kDa α-II-spectrin breakdown product (SBPD) in diaphragm muscle following 12 hours of MV. Note that the SBDP 145 kDa is an α-II-spectrin breakdown product that is specific to calpain cleavage of intact α-II-spectrin. C) The cleaved and active band of caspase-3 in diaphragm muscle at the completion of 12 hours of MV. D) Levels of the 120 kDa α-II-spectrin breakdown product (SBPD) in diaphragm muscle following 12 hours of MV. Note that the SBDP 120 kDa is an α-II-spectrin breakdown product that is specific to caspase-3 cleavage of intact α-II-spectrin. The images above the histograms in Figure 5 are representative western blots of data from the four experimental groups. Values are means ± SEM. * = different (p<0.05) from both Control and MV+Calpain Inhibitor groups. † = different (p<0.05) from both Control and MV+Caspase-3 Inhibitor groups. ‡ = different (p<0.05) from Control group.

HHS Vulnerability Disclosure